NYSE:TARO

Taro Pharmaceutical Industries - TARO Earnings Date, Estimates & Call Transcripts

$30.41

-0.17 (-0.56%)

(As of 02/3/2023 09:05 PM ET)

Add

Compare

Today's Range: $29.74
▼
$30.56
50-Day Range: $27.88
▼
$31.59
52-Week Range: $27.50
▼
$51.08

Volume: 7,000 shs
Average Volume: 9,813 shs
Market Capitalization: $1.14 billion

P/E Ratio: 24.93
Dividend Yield: N/A
Price Target: $35.00

Institutional Ownership

Earnings Per Share Revenue

TARO Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

TARO Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Taro Pharmaceutical Industries Analyst Forecasts

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q4 2023	1	$0.23	$0.23	$0.23

TARO Earnings Date and Information

Taro Pharmaceutical Industries has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 25th, 2023 based off prior year's report dates.

Taro Pharmaceutical Industries Earnings History by Quarter

Export to Excel

Date	Quarter	Consensus Estimate	Reported EPS	Beat/Miss	GAAP EPS	Revenue Estimate	Actual Revenue
5/25/2023 (Estimated)
10/27/2022	Q2 2023	$0.84	($0.07)	($0.91)	($0.07)	$161.02 million	$130.50 million
7/27/2022	Q1 2023	$0.85	$0.37	($0.48)	$0.37	$149.90 million	$156.67 million
5/26/2022	Q4 2022	$0.88	$0.73	($0.15)	$0.73	$147.00 million	$143.26 million
1/27/2022	Q3 2022		$0.70	+$0.70	$0.70		$138.98 million
10/28/2021	9/30/2021	$1.02	$0.66	($0.36)	$0.70	$153.23 million	$131.99 million
7/27/2021	6/30/2021	$0.84	$1.09	+$0.25	$2.68	$137.20 million	$147.11 million

5/18/2021	Q4	$0.92	($0.78)	($1.70)	$2.40	$147.33 million	$148.35 million
1/27/2021	12/31/2020	$1.01	$0.86	($0.15)	$0.86	$152.63 million	$140.15 million
10/28/2020	9/30/2020	$0.77	$1.18	+$0.41	$1.18	$125.30 million	$142.84 million
7/29/2020	6/30/2020	$1.16	($11.37)	($12.53)	$12.89	$158.35 million	$117.63 million
5/19/2020	3/31/2020	$1.53	$1.42	($0.11)	$1.42	$168.25 million	$174.94 million
2/3/2020	Q3	$1.54	$1.76	+$0.22	$1.76	$172.00 million	$147.68 million
11/4/2019	Q2	$1.72	$1.46	($0.26)	$1.46	$168.60 million	$160.85 million
8/8/2019	Q1	$1.96	$1.72	($0.24)	$1.72	$169.80 million	$161.30 million
5/22/2019	Q4	$2.26	$1.52	($0.74)	$1.52	$189.90 million	$179.92 million
2/6/2019	Q3 2019	$1.95	$2.40	+$0.45	$2.40	$174.70 million	$176.38 million
11/5/2018	9/30/2018	$1.96	$1.60	($0.36)	$1.60	$167.40 million	$158.97 million
8/9/2018	6/30/2018	$2.33	$1.71	($0.62)	$1.71	$179.54 million	$154.62 million
5/17/2018	3/31/2018	$1.51	$2.17	+$0.66	$2.17	$166.59 million	$175.22 million
2/7/2018	Q3 2018		$1.37	+$1.37	$2.29		$155.46 million
11/7/2017	Q2 2018		$1.30	+$1.30	$1.30		$169.92 million
8/8/2017	Q1 2018		$1.35	+$1.35	$1.35		$161.32 million
5/22/2017	Q4		$2.05	+$2.05	$2.05		$196.41 million
2/9/2017	Q3 2017		$3.42	+$3.42	$3.42		$220.40 million
11/8/2016	Q2 2017		$3.00	+$3.00	$3.00		$228.79 million
8/10/2016	Q1 2017		$2.59	+$2.59	$2.59	$215.30 million	$233.80 million
5/26/2016	Q4 2016		$2.68	+$2.68	$2.68		$265.07 million
2/10/2016	Q3 2016		$4.41	+$4.41	$4.41	$974.38 million	$258.30 million
11/3/2015	Q2 2016		$3.11	+$3.11	$3.11		$212.06 million
8/6/2015	Q1 2016		$2.42	+$2.42	$2.42	$1.01 billion	$215.30 million
5/26/2015	Q4 2015		$3.56	+$3.56	$3.56	$881.79 million	$244.18 million
2/10/2015	Q3 2015		$3.33	+$3.33	$3.33	$213.60 million	$237.70 million
11/9/2014	Q2 2015		$3.35	+$3.35	$3.35		$250.83 million
8/7/2014	Q1 2015		$0.98	+$0.98	$0.88		$130.23 million
5/27/2014	Q4 2014		$2.10	+$2.10	$2.10	$165.13 million	$187.20 million
2/10/2014	Q3 2014		$2.59	+$2.59	$2.59	$185.70 million	$213.60 million
11/12/2013	Q2 2014		$2.15	+$2.15	$2.15		$205.32 million
8/7/2013	Q1 2014		$1.32	+$1.32	$1.32	$159.15 million	$153.20 million
5/23/2013	Q4 2013		$1.45	+$1.45	$1.80	$145.00 million	$165.10 million
2/4/2013	Q3 2013		$1.98	+$1.98	$1.98

11/1/2012	Q213		$1.46	+$1.46		$138.25 million	$160.97 million
8/6/2012	Q1 2013		$1.41	+$1.41	$1.41
5/24/2012	Q4 2012		$1.06	+$1.06	$1.06
2/10/2012	Q3 2012		$1.42	+$1.42	$1.44
11/10/2011	Q2 2012		$1.31	+$1.31	$1.30
7/26/2011	Q1 2012		$0.81	+$0.81	$0.82
5/26/2011	Q4 2011		$0.58	+$0.58	$0.58
1/28/2011	Q3 2011		$0.11	+$0.11	$0.11
10/29/2010	Q2 2011		$0.46	+$0.46	$0.46
8/23/2010	Q1 2011		$0.46	+$0.46	$0.46
6/14/2010	Q4 2010		$0.25	+$0.25	$0.25
12/2/2009	Q2 2010		$0.24	+$0.24	$0.24
8/10/2009	Q1 2010		$0.31	+$0.31	$0.31
5/22/2009	Q4 2009		$0.27	+$0.27	$0.27
2/10/2009	Q3 2009		$0.65	+$0.65	$0.85
11/11/2008	Q2 2009		$0.31	+$0.31	$0.31

Taro Pharmaceutical Industries Earnings - Frequently Asked Questions

When is Taro Pharmaceutical Industries's earnings date?: Taro Pharmaceutical Industries has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 25th, 2023 based off last year's report dates. Learn more on TARO's earnings history.

How much revenue does Taro Pharmaceutical Industries generate each year?: Taro Pharmaceutical Industries (NYSE:TARO) has a recorded annual revenue of $561.35 million.
How much profit does Taro Pharmaceutical Industries generate each year?: Taro Pharmaceutical Industries (NYSE:TARO) has a recorded net income of $58.27 million. TARO has generated $1.22 earnings per share over the last four quarters.
What is Taro Pharmaceutical Industries's price-to-earnings ratio?: Taro Pharmaceutical Industries (NYSE:TARO) has a trailing price-to-earnings ratio of 24.93 and a forward price-to-earnings ratio of 42.24.

More Earnings Resources from MarketBeat

Earnings Tools:

Earnings By Country:

Latest Articles:

Upcoming Earnings:

Fiserv (2/7/2023)
Vertex Pharmaceuticals (2/7/2023)
BP (2/7/2023)
Linde (2/7/2023)
CME Group (2/8/2023)
CVS Health (2/8/2023)
Dominion Energy (2/8/2023)
Walt Disney (2/8/2023)
Emerson Electric (2/8/2023)
Equinor ASA (2/8/2023)

This page (NYSE:TARO) was last updated on 2/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Taro Pharmaceutical Industries - TARO Earnings Date, Estimates & Call Transcripts

TARO Earnings Estimates and Actuals by Quarter

TARO Estimated and Actual Revenue by Quarter

Taro Pharmaceutical Industries Analyst Forecasts

TARO Earnings Date and Information

Taro Pharmaceutical Industries Earnings History by Quarter

Taro Pharmaceutical Industries Earnings - Frequently Asked Questions

More Earnings Resources from MarketBeat

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info